Cabaletta Bio ^{Priced, Nasdaq: CABA}

We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Our lead CAAR T cell product candidate was designed based on chimeric antigen receptor, or CAR, T cell technology that has been successfully developed and is marketed for the treatment of B cell cancers. We believe our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation platform, has applicability across over two dozen B cell-mediated autoimmune diseases that we have identified. During the past two years, using our CABA platform, we have discovered and developed four product candidates, including our lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris, and three additional product candidates that have demonstrated target engagement in vitro. In order to accelerate product development and access a proven cell therapy manufacturing platform, we have entered into a collaboration with the University of Pennsylvania, or Penn.